Ultragenyx Sells Rare Pediatric Disease Priority Review Voucher for $203 Million

Ultragenyx Pharmaceutical announced it will sell a rare pediatric disease priority review voucher for $203 million, following FDA approval of its treatment for mucopolysaccharidosis type IIIA. The deal is pending customary closing conditions, including antitrust review.

Ultragenyx Pharmaceutical (RARE) sold a priority review voucher for $203M, received after FDA approval of its rare disease therapy, Fayuvi. The agreement was announced Wednesday.

Ultragenyx (RARE) will sell a Rare Pediatric Disease Priority Review Voucher for $203M, received after FDA approval of FAYUVI. The deal, advised by Jefferies, aims to fund rare disease therapies and improve profitability. Shares fell 1.07% to $14.76 in early trading.

Ultragenyx Pharmaceutical (RARE) agreed to sell a Rare Pediatric Disease Priority Review Voucher for $203 million in cash. The voucher, awarded by the FDA in September 2026, is tied to the approval of FAYUVI (UX111) for MPS IIIA. The transaction, subject to closing conditions, aims to monetize the voucher and support strategic priorities.

Ultragenyx Pharmaceutical (RARE) sold a Rare Pediatric Disease Priority Review Voucher for $203M. The voucher was received after FDA approval of FAYUVI, a treatment for Sanfilippo syndrome Type A. This is Ultragenyx's second such sale in a week. The deal is subject to regulatory approval. Jefferies LLC and Gibson Dunn are advisors.

Ultragenyx Pharmaceutical Inc. (RARE) agreed to sell a Rare Pediatric Disease Priority Review Voucher for $203M, pending regulatory approval. The deal aligns with the company's strategy to monetize PRVs to support operations and profitability, according to AI Analyst.